Stem Cell Heart Patch CardioPatch Receives FDA Breakthrough Therapy Designation: Injectable Myocardial Repair as Alternative to Heart Transplant

Stem Cell Heart Patch CardioPatch Receives FDA Breakthrough Therapy Designation: Injectable Myocardial Repair as Alternative to Heart Transplant

November 29, 2030, Osaka — Osaka University's School of Medicine today announced that its CardioPatch stem cell heart patch has received FDA breakthrough therapy designation. The product uses induced pluripotent stem cell (iPSC)-derived cardiomyocytes formed into thin patch sheets, delivered to the heart surface via minimally invasive surgery for treating end-stage heart failure.

Clinical Data

The Phase III clinical trial was conducted at 23 hospitals across Japan, the US, and Germany, enrolling 312 severe heart failure patients with ejection fractions below 30%. Patients were randomized to CardioPatch or standard medical therapy groups.

12-month follow-up data showed that the CardioPatch group's average ejection fraction improved from 28% to 43%, while the medication group declined from 29% to 26%. More critically, 67% of CardioPatch patients improved from NYHA Class III (limited daily activity) to Class II (mild limitation), compared to only 12% in the medication group.

"This is not a cure, but it's the biggest breakthrough in heart failure treatment since heart transplantation," said Professor Yoshiki Sawa of Osaka University's cardiovascular surgery department. Sawa has been leading the CardioPatch project for over 15 years.

Technical Principle

CardioPatch's core is 4-0.8mm thick iPSC-derived cardiomyocyte sheets. Each sheet contains approximately 100 million cardiomyocytes that spontaneously form electrically coupled networks during culture. After attachment to the heart surface, the patches establish blood supply through capillary infiltration and electrical coupling with host cardiomyocytes through gap junctions.

"The patch does not replace damaged myocardium," Sawa explained. "It improves the cardiac microenvironment by secreting angiogenic and anti-fibrotic factors while providing partial contractile assistance."

Safety and Challenges

Three serious adverse events were recorded during the trial: one arrhythmia (controlled with medication), one patch dislocation (requiring secondary surgery), and one immune rejection (patient had previously received non-autologous iPSC-derived patch). Overall safety was deemed acceptable.

The greatest challenge is manufacturing cost. Each CardioPatch requires approximately 6 weeks of cell culture, with per-unit cost around $150,000. Sawa's team is developing automated culture systems targeting cost reduction to under $30,000.

Japan's Ministry of Health, Labour and Welfare is expected to approve CardioPatch in Q1 2031. FDA's timeline has not been announced, but breakthrough therapy designation ensures accelerated review.